摩根大通日本股票研究团队发布日本生物技术与制药行业周报（10月5日至9日）。报告期内制药板块上涨0.6%，与TOPIX（+0.3%）基本持平。武田药品周涨3.5%，因其药物Orzeyful（oveporexton）报销价定为每毫克22,792.5日元（成人通常每日口服两次每次1mg，年费用约1,660万日元）；按158日元/美元折算年价约10.5万美元，低于美国现有同类药物价格，但武田未参与美国政府"最惠国"（MFN）药价协议，故不必然按日本价格定价美国市场。预计美国缉毒局（DEA）将于11月初确定该药管制分类，随后公布批发采购成本（WAC）。
The pharmaceutical sector rose 0.6% WoW, performing in line with TOPIX (+0.3%). Takeda Pharmaceutical rose 3.5% WoW after the reimbursement price of Orzeyful (oveporexton) was set at ¥22,792.5/mg (1mg is typically administered orally twice daily for adults; ¥16.6 million on an annual basis). When converted into dollars, the annual price of $105,000 (at ¥158/$) looks lower than prices of existing US drugs. However, Takeda is not participating in the US administration's most-favored-nation (MFN) drug pricing agreement, so we do not think it will necessarily set the US price in line with the price in Japan. We expect the US Drug Enforcement Administration (DEA) to determine the drug's classification by early November, and we expect the wholesale acquisition cost (WAC) to be announced after this decision. We do not expect Takeda's 2Q results to yield any particular surprises. We forecast core operating profit of ¥346.9 billion (Bloomberg consensus estimate: ¥319.3 billion) and operating pr